{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Gold JAW"],"funding":["Centers for Disease Control and Prevention"],"pagination":["ofac215"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9253885"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["9(7)"],"pubmed_abstract":["<h4>Background</h4>Invasive mold diseases (IMDs) cause severe illness, but public health surveillance data are lacking. We describe data collected from a laboratory-based, pilot IMD surveillance system.<h4>Methods</h4>During 2017-2019, the Emerging Infections Program conducted active IMD surveillance at 3 Atlanta-area hospitals. We ascertained potential cases by reviewing histopathology, culture, and <i>Aspergillus</i> galactomannan results and classified patients as having an IMD case (based on European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group [MSG] criteria) or a non-MSG IMD case (based on the treating clinician's diagnosis and use of mold-active antifun"],"journal":["Open forum infectious diseases"],"pubmed_title":["Clinical Characteristics, Health Care Utilization, and Outcomes Among Patients in a Pilot Surveillance System for Invasive Mold Disease-Georgia, United States, 2017-2019."],"pmcid":["PMC9253885"],"funding_grant_id":["CDC-RFA-CK17-1701"],"pubmed_authors":["Lockhart SR","Gold JAW","Pouch SM","Montero AJ","Oliver NT","Revis A","Jordan A","Berkow EL","Lysen C","Beer KD","Thomas S","Blakney RA","Chambers T","Farley MM","Perry L","Webster AS","Bentz ML","Kelly HC","Jackson BR","Nunnally NS"],"additional_accession":[]},"is_claimable":false,"name":"Clinical Characteristics, Health Care Utilization, and Outcomes Among Patients in a Pilot Surveillance System for Invasive Mold Disease-Georgia, United States, 2017-2019.","description":"<h4>Background</h4>Invasive mold diseases (IMDs) cause severe illness, but public health surveillance data are lacking. We describe data collected from a laboratory-based, pilot IMD surveillance system.<h4>Methods</h4>During 2017-2019, the Emerging Infections Program conducted active IMD surveillance at 3 Atlanta-area hospitals. We ascertained potential cases by reviewing histopathology, culture, and <i>Aspergillus</i> galactomannan results and classified patients as having an IMD case (based on European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group [MSG] criteria) or a non-MSG IMD case (based on the treating clinician's diagnosis and use of mold-active antifun","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Jul","modification":"2025-04-26T13:04:38.837Z","creation":"2022-07-21T10:45:16.53Z"},"accession":"S-EPMC9253885","cross_references":{"pubmed":["35794945"],"doi":["10.1093/ofid/ofac215"]}}